Oxford BioDynamics Plc (AIM:OBD)
London · Delayed Price · Currency is GBP · Price in GBX 0.1147
-0.0003 (-0.26%)
Sep 25, 2026, 11:49 AM GMT
Oxford BioDynamics Employees
Oxford BioDynamics had 37 employees as of March 31, 2026. The number of employees decreased by 4 or -9.76% since the number was reported on September 30, 2025.
Employees
37
Change
-4
Growth
-9.76%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
15.46M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 37 | -4 | -9.76% |
| Sep 30, 2025 | 41 | -10 | -19.61% |
| Sep 30, 2024 | 51 | 6 | 13.33% |
| Sep 30, 2023 | 45 | 1 | 2.27% |
| Sep 30, 2022 | 44 | 5 | 12.82% |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IXICO | 79 |
| SkinBioTherapeutics | 41 |
| Arecor Therapeutics | 33 |
| Aptamer Group | 30 |
| Palatin Technologies | 29 |
| Fusion Antibodies | 27 |
| Hemogenyx Pharmaceuticals | 16 |
| ImmuPharma | 7 |
Oxford BioDynamics News
- 2 years ago - Oxford Biodynamics to present on its line of EpiSwitch® products for companion diagnostics in cancer immunotherapy at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics in Boston, MA. - Business Wire
- 2 years ago - Oxford BioDynamics part of consortium shortlisted for Strategic Government Initiative to Improve Cancer Immunotherapy - Business Wire